The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
About PRA in China
PRA has been helping to bring to market everything from niche treatments and therapies to blockbuster drugs for more than 30 years.
As a top five CRO, we have worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of more than 75 such drugs.
PRA provides the local and global presence you need, with 15,500+ employees covering over 85 countries, combined with an in-depth knowledge of local regulations, standards of care, and the cultural customs our clients expect.
Our operational and therapeutic expertise, and future-thinking approach to data-driven drug development, enables us to provide high quality global services.
PRA’s operations are fully integrated to consistently execute global development programs. We support our clients’ development programs in a variety of ways.
World-class, therapeutic expertise which includes our own drug development experts, regional key opinion leaders, networks of proven investigators, and best-in-class third party suppliers
Our customized Embedded Solutions™ model provides scalable solutions to improve operational efficiencies and business continuity while allowing clients to maintain flexibility and control
Strong global program leadership and the ability to interact seamlessly across borders
A state-of-the-art global IT infrastructure that allows ease of communication and transparent access to data
A flexible and scalable Biometrics organization which allows us to support our clients dynamically and best meet their personal needs while managing costs
Offices with local staff who are intimately familiar with local regulatory requirements for study start-up while simultaneously connected to all of PRA’s global resources through our integrated systems
Explore PRA in China
Our Solutions and Capabilities
Biometrics forms a centralized, global model that integrates Portfolio Management, Biostatistics and Programming, Data Operations, and Medical…
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…
The Patient Voice - Engaging Rare Disease Patients to Accelerate Clinical Trial Enrollment
Rare disease patients face a number of unique challenges and complexities of their conditions, Often, this means that their families and advocates…